What GenomeScan does

GenomeScan BV is a Dutch genomics services provider headquartered in Leiden, Netherlands, founded in 2002 and operating from an ISO/IEC 17025 accredited laboratory. The company delivers customized Next Generation Sequencing (NGS) services using Illumina platforms (NovaSeq 6000, NextSeq 500) and Oxford Nanopore long-read technology, covering Whole Genome Sequencing, Whole Exome Sequencing, RNA sequencing (including single-cell, FFPE, and ultra-low input), epigenetics, and microbiome profiling. Proprietary technical assets include Unique Molecular Identifier (UMI) based error correction and a 523-gene Comprehensive Cancer Panel for tumor profiling, TMB, and MSI scoring. Specialized diagnostic sub-brands target oncology (OncoNeoantigen, Onco-ctTrace, OncoPair) and neurology (Neuro-GBA1Screen).

The company's business model is project-based professional services: customers describe their NGS project via contact forms or email, the technical team consults on sequencing approach, samples are shipped to the Leiden facility, and results are delivered through a secure customer portal. Pricing is not publicly disclosed; quotes are project-specific. GenomeScan serves three primary customer segments at equal weight — pharmaceutical and biotechnology companies, healthcare providers and hospitals, and academic institutions — with anchor relationships including Leiden University Medical Center (LUMC) and Erasmus MC as shareholders, and Amsterdam UMC as an outsourcing customer since January 2021. International customers include Stanford University Medical Center, King's College London, the Netherlands Cancer Institute, and the International Barcode of Life consortium.

Go-to-market is sales-led, driven by content marketing through a blog and publication campaigns, conference attendance across European venues (ESHG, ESGCT, Festival of Biologics, Swiss Biotech Day, European Congress of Pathology), email outreach, and PR via press releases and academic publications. It is a small organization of 11-50 employees that has operated for over 15 years without disclosed external venture funding, with Crédit d'Impôt Recherche (CIR) accreditation in France (2023-2025), IVDR certification, and GCLP compliance supporting pharma/biotech and clinical diagnostics customers. Recent strategic activity includes the NEOVACC personalized lung cancer vaccine trial (2026) and ISO 23418 food-safety working group participation, indicating measured expansion into new verticals.

Name

GenomeScan

Legal name

GenomeScan BV

Website

https://genomescan.nl

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

11–50 employees

Short description

GenomeScan BV is a Dutch ISO/IEC 17025 accredited Next Generation Sequencing services provider in Leiden, Netherlands, offering customized DNA, RNA, epigenetics, and microbiome sequencing with integrated bioinformatics to pharmaceutical, healthcare, and academic customers. The firm also operates oncology and neurology diagnostic sub-brands.

Ownership category

akta.pro rank

Product category

Genomics Sequencing Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA)

akta.pro secondary industries

Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD), Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)

Keywords

• Next generation sequencing
• DNA sequencing services
• RNA sequencing services
• Bioinformatics analysis
• Genomics diagnostics

Headquarters

HQ city

Leiden

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. NGS Sequencing Services: GenomeScan provides customized next generation sequencing services including Whole Genome Sequencing, Whole Exome Sequencing, RNA Sequencing, Long-Read Sequencing, Epigenetics, and Microbiome profiling. Revenue is generated through project-based pricing where customers outsource their sequencing needs to GenomeScan's ISO/IEC 17025 accredited laboratory.
2. Bioinformatics Analysis: In-house bioinformatics team provides data analysis, interpretation, and reporting services integrated with sequencing workflows or as standalone service

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

GenomeScan provides outsourced Next Generation Sequencing (NGS) services and matched bioinformatics analysis from its ISO/IEC 17025-accredited laboratory in Leiden, Netherlands. The company performs DNA, RNA, epigenetics, single-cell, and microbiome sequencing for pharmaceutical, biotech, hospital, and academic clients, complemented by specialized oncology and neurology diagnostic panels and Genetic QC solutions.

Product overview

GenomeScan is a genomics solutions provider offering customizable Next Generation Sequencing (NGS) services. The core offering consists of DNA Sequencing services (Whole Genome Sequencing, Whole Exome Sequencing, Long Read Sequencing), RNA Sequencing services (Gene Expression Analysis, Total Transcriptome, Ultra-low Input Transcriptomics, FFPE Tissue RNA-Seq, Single Cell Sequencing), Epigenetics, and Microbiome sequencing (Whole Metagenome Sequencing, 16S-V4 Bacterial Profiling). These research services are supported by Bioinformatics/IT Services and Genetic QC add-on modules. The company also offers specialized diagnostic products under sub-brands including GenomeScan OncoNeoantigen, GenomeScan Onco-ctTrace, and GenomeScan OncoPair for oncology applications, and GenomeScan Neuro-GBA1Screen for neurology. A Comprehensive Cancer Panel targeting 523 genes is available for tumor profiling diagnostics.

Differentiator

Problem solved

Functional benefit

Brands

• GenomeScan OncoNeoantigen: Oncology neoantigen prediction service for personalized cancer immunotherapy.
• GenomeScan Onco-ctTrace
• GenomeScan OncoPair
• GenomeScan Neuro-GBA1Screen
• Genetic QC

Products and services

• Whole Genome Sequencing (WGS) Comprehensive DNA sequencing service that analyzes the entire genome to identify genetic variants, structural variants, and other genomic alterations for research and clinical customers.
• Whole Exome Sequencing (WES) Targeted DNA sequencing service that sequences all protein-coding regions of the genome to identify disease-causing mutations for research and clinical customers.
• Long Read Sequencing Sequencing service that generates reads of thousands to millions of base pairs, enabling better resolution of repetitive regions, structural variants, and full-length transcripts for research customers.
• Gene Expression Analysis RNA sequencing service that quantifies gene expression levels to support understanding of biological processes and disease mechanisms.
• Total Transcriptome Comprehensive RNA sequencing service that captures all RNA transcripts, including coding and non-coding RNAs, for research customers.
• Ultra-low Input Transcriptomics RNA sequencing service designed for samples with minimal starting material, enabling analysis of precious or limited samples.
• FFPE Tissue RNA-Seq RNA sequencing service optimized for formalin-fixed paraffin-embedded tissue samples, commonly used in clinical archives and retrospective studies.
• Single Cell Sequencing RNA sequencing service that analyzes gene expression at individual cell resolution to understand cellular heterogeneity in research samples.
• Epigenetics Services Analysis of epigenetic modifications including DNA methylation and chromatin structure alterations for research customers.
• Whole Metagenome Sequencing Sequencing service that characterizes the complete genetic content of microbial communities in samples for research customers.
• 16S-V4 Bacterial Profiling Targeted sequencing of the 16S rRNA gene region for taxonomic profiling of bacterial communities in microbiome samples.
• Bioinformatics/IT Services Standalone data analysis, pipeline development, and bioinformatics support service for NGS projects, offered alongside or independent of GenomeScan's sequencing workflows.
• GenomeScan OncoNeoantigen Oncology diagnostic service focused on neoantigen prediction and analysis to support personalized cancer immunotherapy applications.
• GenomeScan Onco-ctTrace Circulating tumor DNA analysis service for cancer monitoring and detection in oncology and clinical research applications.
• GenomeScan OncoPair Oncology diagnostic service for paired sample analysis supporting cancer research studies.
• GenomeScan Neuro-GBA1Screen Neurology diagnostic service for screening GBA1 gene variants associated with Parkinson's disease and other neurological disorders.
• Genetic QC Next Generation Sequencing-based genetic quality control solutions to ensure data reliability for biosafety and other QC use cases.
• Comprehensive Cancer Panel NGS-based tumor profiling panel targeting 523 genes to detect SNVs, insertions, deletions, CNVs, TMB, and MSI scores across multiple tumor types.

Quantifiable outcome

• 48-hour diagnostic turnaround capability for certain applications
• +2 more outcomes

Named customers8 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

14 partnerships are on record, tiered core, major and supporting.

• Leiden University Medical Center (LUMC)coreStrategic or Co-development PartnerLUMC is both a shareholder and key strategic partner in GenomeScan. The collaboration focuses on molecular diagnostics and R&D, with LUMC performing fast and sustainable molecular diagnostics under GenomeScan's ISO-accreditation. The partnership enables access to cutting-edge diagnostic technologies and supports innovation in genomic applications.
• Erasmus MCcoreStrategic or Co-development PartnerErasmus MC acquired shares in GenomeScan and joined with LUMC to co-participate in the company. The collaboration aims to drive innovation in healthcare through technology investments, optimize capital equipment utilization, and develop new applications for R&D and diagnostics in an international scientific environment.
• Amsterdam UMCmajorStrategic or Co-development PartnerAmsterdam UMC and GenomeScan have been collaborating since January 2021 for genome sequencing. Amsterdam UMC outsources NGS library sequencing for both its AMC and VUmc locations to GenomeScan, which performs reliable and sustainable clinical genome analysis under ISO/IEC 17025 accreditation.
• IlluminacoreTechnology or IntegrationIllumina is listed as a collaborator with their logo displayed on the GenomeScan website. GenomeScan uses Illumina sequencing platforms including NovaSeq 6000 and NextSeq 500 for various NGS applications.
• Oxford Nanopore TechnologiescoreTechnology or IntegrationOxford Nanopore Technologies is listed as a collaborator with their logo displayed. GenomeScan offers long-read sequencing using Oxford Nanopore Technology for applications including adeno-associated virus analysis, whole genome sequencing, targeted sequencing, epigenetics, and transcriptomics.
• AgilentsupportingTechnology or IntegrationAgilent is listed as a collaborator with their logo displayed on the website, indicating technology partnership for sequencing solutions.
• New England Biolabs (NEB)supportingTechnology or IntegrationNEB is listed as a collaborator with their logo displayed, indicating a supplier/partnership relationship for laboratory reagents and solutions.
• Twist BiosciencesupportingTechnology or IntegrationTwist Bioscience is listed as a collaborator with their logo displayed, indicating a partnership for synthetic biology or sequencing target enrichment solutions.
• myNEOmajorStrategic or Co-development PartnermyNEO is listed as a collaborator. They provide computational tumor-targeting tools used in combination with GenomeScan's sequencing capabilities for personalized cancer vaccine development, including the NEOVACC Phase I clinical trial.
• TouchlightmajorTechnology or IntegrationTouchlight provided the innovative 'doggybone DNA' technology used in the world's first personalized lung cancer vaccine developed through the NEOVACC trial. GenomeScan contributed sequencing and bioinformatics expertise to this pioneering project.
• University of LiverpoolmajorStrategic or Co-development PartnerResearchers and clinicians from the University of Liverpool administered the world's first personalized lung cancer vaccine as part of the NEOVACC Phase I clinical trial. GenomeScan contributed to this major development through sequencing and bioinformatics support.
• Clatterbridge Cancer CentremajorStrategic or Co-development PartnerClatterbridge Cancer Centre clinicians administered the world's first personalized lung cancer vaccine to patient Chris Jones. GenomeScan provided bioinformatics and sequencing support for this clinical trial.
• UCBsupportingTechnology or IntegrationUCB is listed as a collaborator with their logo displayed on the website, indicating a partnership relationship for biotech/pharmaceutical collaboration.
• Batavia BiosciencessupportingTechnology or IntegrationBatavia Biosciences is listed as a collaborator with their logo displayed, indicating a partnership for biotech/pharmaceutical services.

Scale indicators3 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Macrogen: Korea-headquartered NGS service provider serving pharma and academia worldwide with WGS, WES, RNA-Seq, and bioinformatics — same core B2B service model and customer base as GenomeScan.
• Novogene: China-founded NGS services provider with European operations offering WGS, WES, RNA-Seq, single-cell, and bioinformatics to pharma/biotech — direct global competitor for outsourced sequencing.
• CeGaT: German NGS service and diagnostics provider with ISO accreditation serving pharma, clinicians, and academic researchers — closely comparable European peer with similar menu and regulatory positioning.
• BaseClear: Netherlands-based genomics services company specializing in microbial genomics, WGS, and microbiome sequencing — direct regional competitor headquartered in Leiden's broader biotech ecosystem.
• Genewiz (Azenta Life Sciences): NGS service brand now part of Azenta, offering Sanger, WGS, RNA-Seq, and synthetic biology to pharma and academia — direct competitor in custom NGS outsourcing.
• Eurofins Genomics: Global genomics services division of Eurofins Scientific offering DNA sequencing, RNA sequencing, and bioinformatics to pharma and academic customers — directly comparable menu of custom NGS services at much larger scale.

Regional players

• Source BioScience: UK-based genomics and diagnostics services provider offering sequencing and laboratory services — comparable menu but focused on UK clinical diagnostics and life sciences market.
• Fasteris: Swiss NGS service provider offering DNA sequencing, RNA-Seq, and bioinformatics to academic and pharma clients — comparable menu, smaller scale, geographically complementary.

Broad incumbents

• Illumina: Sequencing platform vendor whose NovaSeq and NextSeq instruments GenomeScan relies on; also offers its own services through Illumina's Clinical Services Laboratory — vertical competitor as well as strategic supplier.
• BGI Genomics: China-based global genomics giant operating the DNBSEQ platform and offering WGS, WES, and clinical sequencing at massive scale — represents the upper-end pricing-pressure benchmark for European NGS service providers.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/genomescan
• LinkedInlinkedin.com/company/genomescan

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GenomeScan